Replimune Group (NASDAQ:REPL) Director Kapil Dhingra Sells 21,500 Shares of Stock

Replimune Group, Inc. (NASDAQ:REPL) Director Kapil Dhingra sold 21,500 shares of the company’s stock in a transaction that occurred on Monday, November 2nd. The shares were sold at an average price of $19.00, for a total value of $408,500.00. Following the sale, the director directly owned 21,669 shares in the company, valued at approximately $411,711. This represents a 49.80% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Replimune Group Stock Up 6.0%

REPL traded up $1.16 during trading hours on Tuesday, hitting $20.65. 4,728,562 shares of the stock were exchanged, compared to its average volume of 2,758,501. The stock has a 50-day simple moving average of $13.79 and a 200-day simple moving average of $9.47. The company has a debt-to-equity ratio of 0.59, a quick ratio of 6.90 and a current ratio of 7.11. Replimune Group, Inc. has a 12 month low of $1.50 and a 12 month high of $21.26.

Replimune Group (NASDAQ:REPL) last released its earnings results on Wednesday, October 28th. The company reported ($0.54) earnings per share for the quarter, beating the consensus estimate of ($0.78) by $0.24. Sell-side analysts anticipate that Replimune Group, Inc. will post -2.40 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have commented on the company. Piper Sandler upgraded Replimune Group from a “hold” rating to a “strong-buy” rating in a research note on Friday, July 31st. Wolfe Research raised Replimune Group to an “outperform” rating in a report on Tuesday, August 4th. Wedbush upgraded Replimune Group from a “neutral” rating to an “outperform” rating and set a $12.00 price target on the stock in a research report on Friday, August 7th. JPMorgan Chase & Co. raised their price target on Replimune Group from $20.00 to $21.00 and gave the stock an “overweight” rating in a report on Wednesday, August 26th. Finally, Leerink Partners raised their price target on Replimune Group from $19.00 to $31.00 and gave the stock an “outperform” rating in a report on Thursday, October 29th. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $14.33.

Institutional Investors Weigh In On Replimune Group

Institutional investors have recently bought and sold shares of the stock. AXQ Capital LP increased its stake in Replimune Group by 4.1% during the 2nd quarter. AXQ Capital LP now owns 27,121 shares of the company’s stock valued at $300,000 after buying an additional 1,056 shares during the period. Walleye Capital LLC raised its position in shares of Replimune Group by 3.2% during the 1st quarter. Walleye Capital LLC now owns 71,592 shares of the company’s stock worth $548,000 after buying an additional 2,192 shares in the last quarter. China Universal Asset Management Co. Ltd. raised its position in shares of Replimune Group by 30.8% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 17,191 shares of the company’s stock worth $223,000 after buying an additional 4,050 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of Replimune Group in the 3rd quarter worth approximately $64,000. Finally, Allworth Financial LP acquired a new stake in shares of Replimune Group in the 2nd quarter worth approximately $62,000. Institutional investors and hedge funds own 92.53% of the company’s stock.

About Replimune Group

Replimune Group, Inc is a clinical-stage biotechnology company developing cancer immunotherapies designed to stimulate the immune system to recognize and attack tumors. The company’s approach focuses on oncolytic immunotherapy, using genetically engineered viruses intended to selectively infect and destroy tumor cells while also activating broader antitumor immune responses.

Replimune’s lead product candidate is RP1, also known as vusolimogene oderparepvec, an engineered oncolytic herpes simplex virus type 1 designed to replicate within tumors and promote systemic immune activity.